Oragenics, Inc. Announces the Completion of Enrollment for its ProBiora3® Clinical Trial at the Univ

Oragenics, Inc. Announces the Completion of Enrollment for its ProBiora3^®Clinical Trial at the University of Washington

TAMPA, Fla.--(BUSINESS WIRE)-- Florida-based biopharmaceutical company Oragenics, Inc. (OTCBB: ORNI) www.oragenics.com today announced the completion of the enrollment of their latest ProBiora3 human clinical study. The company is sponsoring the University of Washington School of Dentistry to conduct a 12 week, double-blind, placebo-controlled, randomized clinical study on ProBiora3. The study is assessing various microbiological, cosmetic and oral health indices on approximately 50 healthy subjects to further substantiate the benefits of ProBiora3. ProBiora3 is the result of over 25 years of research and is the active ingredient in Oragenics' Evora brand of oral health products. ProBiora3 is a patented blend of three unique strains of beneficial bacteria that are naturally found in healthy mouths.

"The University of Washington conducts a wide range of research in oral clinical sciences and fosters productive interactions with leaders in the health care industry," said Dr. Linda LeResche, Associate Dean for Research at the UW School of Dentistry. "Probiotics are an intriguing field of study in oral health, and we are pleased that Dr. Whasun 'Sun' Oh Chung, Research Associate Professor in the Department of Oral Health Sciences, is participating as principal investigator of this Oragenics-funded clinical trial in our Regional Clinical Dental Research Center."

John N. Bonfiglio, Ph.D., Oragenics Chief Executive Officer, commented, "Oragenics is pleased to engage in this ProBiora3 clinical trial in collaboration with the University of Washington. We expect that these data will corroborate previous positive results obtained from human and animal studies conducted by both Oragenics and independent investigators. We also believe this study will reinforce the claim that ProBiora3, the active ingredient in EvoraPlus® and EvoraPro® promotes oral health by helping to maintain a naturally balanced oral microflora." The Company anticipates that this study will provide additional evidence that the probiotics in ProBiora3 can inhibit those organisms of the oral cavity that have been previously associated with bad breath.

About Oragenics, Inc.

Oragenics, Inc. is focused on becoming the world leader in probiotics for oral health for humans and pets and in novel antibiotics against infectious disease. Oragenics, Inc. develops, markets and sells proprietary probiotics specifically designed to enhance oral health for humans and pets, under the brand names Evora and ProBiora in over 13 countries worldwide. Oragenics, Inc. has established an exclusive worldwide channel collaboration for lantibiotics, a novel class of broad spectrum antibiotics, with Intrexon Corporation, a synthetic biology company.

For more information, visit www.oragenics.com. Follow Oragenics on Facebook and Twitter.

About the University of Washington.

The University of Washington School of Dentistry is one of only two dental schools in the Pacific Northwest, is a worldwide leader in dental education and research, consistently ranking among the top U.S. dental schools for National Institutes of Health funding. The school furnishes comprehensive clinical care and also plays a major role in public health through its service to people with disabilities and efforts to improve access to care for underserved communities.

Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect the Company's current views with respect to future events and financial performance. These forward-looking statements are based on management's beliefs and assumptions and information currently available. The words "believe," "expect," "anticipate," "intend," "estimate," "project" and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to our ability to raise additional capital to sustain our operations beyond June 30, 2012 and those set forth in our most recently filed annual report on Form 10-K and quarterly report on Form 10-Q, and other factors detailed from time to time in filings with the U.S. Securities and Exchange Commission. We expressly disclaim any responsibility to update forward-looking statements.

Corporate Contact:
Oragenics, Inc.
Michael Sullivan, Chief Financial Officer, 813-286-7900 x246
Direct: 813-786-6431
msullivan@oragenics.com
or
Investor Contact:
LaunchPad IR
Robert Giordano, President, 1-800-625-2236 x7770
Direct: 917-327-3938
rgiordanonyc@gmail.com
or
University of Washington Contact:
UW School of Dentistry
Steve Steinberg, Director of Communications, 206-616-0827
ss55@u.washington.edu

KEYWORDS: United States North America Florida

INDUSTRY KEYWORDS:

The article Oragenics, Inc. Announces the Completion of Enrollment for its ProBiora3® Clinical Trial at the University of Washington originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.